Cambridge · Seed–Late Stage · 13 people tracked
Find your way into AbbVie
3,301 people in our graph share verified history with the AbbVie team — schools, employers, funds. One of them is your warm intro.
Investment thesis
Very early discovery and preclinical therapeutics company-creation partner tightly integrated with AbbVie R&D, offering founders direct in-house expertise in oncology, immunology, neuroscience and development/commercial infrastructure.
Team · 13 people
from curated & public directories
Founder mafia
The AbbVie mafia →13 people who came through AbbVie went on to found or lead other companies.
+ 1 more
What they invest in
from 7 of 8 portfolio companiesBiotech ×7AI & Machine Learning ×1Healthtech ×1Medical Devices ×1
HQs:United States×4Italy×1
Investments · 16 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 12024 · 12020 · 22018 · 22017 · 310 dated
Enanta Pharmaceuticals is a biotechnology company that discovers and develops small-molecule therapeutics using chemistry-based research to treat diseases with high unmet medical need.
Biotech
Jay R. Luly(President, Director and Chief Executive Officer)Yat Sun Or(Chief Scientific Officer)Scott T. Rottinghaus(Chief Medical Officer)inMatthew P. Kowalsky(Chief Legal Officer and Corporate Secretary)Tara L. Kieffer(Chief Product Strategy Officer)inBrendan Luu(Chief Business Officer)in
Co-investorsSofinnova Ventures
Exicure is a publicly-traded holding company that previously developed nucleic acid therapies and has since divested its historical biotechnology assets; it is now pursuing growth through acquisitions and partnerships, including a recent investment in GPCR Therapeutics USA, which is developing small molecule therapies for blood cancers and multiple myeloma.
BiotechSkokie, US
Chad A. Mirkin(Director)C. Shad Thaxton(Director)David A. Giljohann(Chief Executive Officer)inDavid S. Snyder(Chief Financial Officer)inPercy Van Crocker, Jr.(Vice President, Commercial Development)
BoardJay Venkatesan(Director)
Co-investorsInnovation EndeavorsPurple Arch VenturesRockPort Capital Partners
Light Horse Therapeutics is a drug discovery company applying scientific expertise and innovation to advance healthcare through collaborative development.
AI & Machine LearningBiotechMedical Devices
Co-investorsTaiho Ventures, LLCMubadala CapitalVersant Ventures
CAR-Macrophage cellular therapeutics with initial oncology focus (NASDAQ: CARM).
BiotechPhiladelphia, US
Steven Kelly(Executive Officer, Director)in
BoardMargarita Chavez(Director)inEran Nadav(Director)Althea Stillman(Director)Jacob Gunterberg(Director)Regina Hodits(Director)in
Co-investorsAgent CapitalAju IB Invesment CorporationAnzu PartnersGrazia Equity GmbHHealthCapMRL Ventures Fund+3 more
Enthera Srl is a privately held pharmaceutical company founded in 2016 and based in Milan, Italy.
BiotechHealthtechMilan, IT
Co-investorsSofinnova PartnersIndaco Venture PartnersRoche Venture FundJDRF T1D Fund
Nitrase Therapeutics is a clinical-stage biopharmaceutical company using its NITROME platform to develop therapeutics based on nitrases, a class of enzymes it discovered that drive protein nitration.
BiotechHealthtechLongevity
Irene Griswold-Prenner(Founder & Chief Executive Officer)in
Co-investorsMission BiocapitalSofinnova PartnersDementia Discovery FundMission Bay Capital
BiotechGreenville, US
Kevin Weeks(Executive Officer, Director)Katherine Warner(Executive Officer)Joshua Resnick(Director)Michael Solomon(Director)John Gustofson(Director)
Co-investorsHatteras Venture PartnersIllumina VenturesM VenturesMC Healthcare VenturesPappas CapitalSV Health Investors+2 more
BiotechLexington, US
Victoria M. Richon(Executive Officer, Director)in
BoardCameron Wheeler(Director)Jonathan Root(Director)Laurence Lasky(Director)
Co-investorsAvego BioScience CapitalOUP (Osage University Partners)Peregrine VenturesNovartis Venture FundThe Column Group
Stylus Medicine develops in vivo genetic medicines using engineered recombinases, with initial focus on creating CAR-T therapies delivered via lipid nanoparticles for oncology, autoimmune, and genetic diseases.
BiotechDigital HealthMedical Devices
Michael C. Bassik, Ph.D.(Scientific Founder)inEmile Nuwaysir, Ph.D.(Chairman & Chief Executive Officer)inJason Fontenot, Ph.D.(Chief Scientific Officer)
Co-investorsBrainstorm VenturesKhosla VenturesNeva Sgr.RA CapitalTachyon Ventures
Ten63 develops drug-discovery technology that combines generative chemistry with quantum-accurate molecular simulation, including BEYOND (a large quantum chemistry model) and Sentinel (a virtual CSO for target selection), to design therapeutics against previously undruggable targets.
AI & Machine LearningBiotechDeep TechDurham, US
Mark A. Hallen(Executive Officer, Director)inMarcel Frenkel(Executive Officer, Director)Damien Petty(Director)inJia Wei Xu(Director)
Co-investorsCape Fear BioCapitalDFJ DragonFundDraper AssociatesDuke Capital PartnersHatteras Venture PartnersAlexandria+4 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Aquinnah PharmaceuticalsCaraway TherapeuticsLeal TherapeuticsLodo TherapeuticsParagen BioPetra Pharma
Exits · 2
2 IPOsEnanta PharmaceuticalsNASDAQ: ENTAExicureNASDAQ: XCUR
Portfolio news
latest coverage across their companiesRibon Therapeutics · geekwire.com · Aug 14, 2026
Enanta Pharmaceuticals · dailypolitical.com · Aug 2, 2026
Exicure · stocktitan.net · Mar 25, 2026
Carisma Therapeutics · bizjournals.com · Dec 16, 2025
Stylus Medicine · bio-itworld.com · May 30, 2025
IPO stake values · per SEC filings · 2
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Enanta Pharmaceuticals | 6.4% | $14.00 | Mar 2013 | $15M |
| Exicure | — | $3.00 | Jan 2018 | $5.8M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has AbbVie made?
- AbbVie has 8 tracked investments, 2 of which have exited.
- What stage does AbbVie invest at?
- AbbVie invests at the Seed, Series A, Late Stage stages.
- What is AbbVie's typical check size?
- AbbVie typically writes checks of $300K – $3M.
- What sectors does AbbVie focus on?
- AbbVie focuses on Biotech.
- Where is AbbVie located?
- AbbVie is headquartered in Cambridge, US.
- Does AbbVie lead rounds?
- AbbVie typically participates in rounds rather than leading them.
Co-investors · 6
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
Hatteras Venture Partners is a venture capital firm focused on early-stage life sciences and healthcare companies, backing therapeutics, diagnostics, and businesses aiming to transform healthcare delivery and innovation.
M Ventures is the corporate venture arm of Merck KGaA based in Darmstadt, Germany, operating from offices in Amsterdam, the US, and Israel. The firm invests globally across early-stage companies and spin-offs in areas aligned with Merck's core business, taking active roles in portfolio company development.
RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.
Morpheus Ventures is a venture capital fund that backs early-stage companies and supports founders through the challenges of scaling toward hyper-growth.
Agent Capital is a healthcare venture capital firm that invests in novel, differentiated therapeutics and treatments addressing unmet patient needs across all stages of development.
Firms observed investing alongside AbbVie, from public investor directories. Shared companies are the overlap with AbbVie's recorded portfolio.
Similar investors
8VC is a venture capital firm investing across logistics, life sciences, healthcare, IT infrastructure, and government/defense, guided by its Smart Enterprise thesis focused on data integration and platform network effects.
Andreessen Horowitz (a16z) is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz, known for pioneering the platform model with a large team of operators supporting founders across stages.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Bessemer Venture Partners is a global venture capital firm that partners with entrepreneurs across enterprise, consumer, and healthcare sectors from early stages through growth.
Blume Ventures is a seed and pre-Series A investment firm headquartered in Mumbai that focuses on early-stage companies in India.